Search Results

Ask a specific question about this device

OsteoFlo HydroFiber is a bone void filler intended for use in osseous defects of the skeletal system that are not intrinsic to the stability of the bony structure i.e., the extremities, pelvis, intervertebral disc space, and posterolateral spine. These defects may be surgically created or the result of traumatic injury to the bone. OsteoFlo HydroFiber is indicated to be packed gently into bony voids or gaps of the extremities, pelvis, posterolateral spine, or intervertebral disc space, and may be used either standalone or in combination with autograft as a bone graft extender. The device is resorbed and replaced with host bone during the healing process. When used in intervertebral body fusion procedures, OsteoFlo HydroFiber must be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler.

The OsteoFlo® HydroFiber™ is a resorbable bone void filler designed to be placed in bony defects, either surgically created (i.e., tumor removal), or the result of traumatic injury. The single-use device is supplied sterile and dry. The device requires mixing with aqueous solution (autograft, saline, blood, or bone marrow aspirate) prior to use. OsteoFlo HydroFiber may be used as standalone, equivalent to autograft, in conjunction with autograft, or as a bone graft extender.

It appears there's a misunderstanding. The provided FDA 510(k) clearance letter for the OsteoFlo HydroFiber device is for a Resorbable Calcium Salt Bone Void Filler Device, which is a physical implantable device.

The request asks for information typically associated with AI/ML-based medical devices, particularly regarding:

• A table of acceptance criteria and reported device performance (often including metrics like sensitivity, specificity, AUC for AI models)
• Sample sizes for test sets, data provenance
• Expert involvement for ground truth establishment (e.g., radiologists for image interpretation)
• Adjudication methods
• Multi-reader multi-case (MRMC) studies
• Standalone performance (algorithm only) vs. human-in-the-loop performance
• Types of ground truth (e.g., pathology, outcomes data)
• Training set sample size and ground truth establishment

The provided FDA letter does not contain any information related to AI/ML software performance or studies. Instead, it lists non-clinical performance data for a physical medical device, such as:

• Biocompatibility
• Sterilization validation
• Packaging validation
• Shelf-life testing
• Endotoxin validation
• Material characterization
• Dimensional stability assessment
• In vivo evaluation (Rabbit Metaphyseal Defect Model)
• Pyrogenicity Testing

Therefore, I cannot fulfill your request based on the provided text, as the document describes the clearance of a physical bone void filler, not an AI/ML software device. The acceptance criteria and performance studies mentioned in the document are for the physical properties and biological interactions of an implantable material, not for the diagnostic or analytical performance of an AI algorithm.

Ask a specific question about this device

OsteoFlo HydroFiber is a bone void filler intended for use in osseous defects of the skeletal system that are not intrinsic to the stability of the bony structure i.e., the pelvis, intervertebral disc space, and posterolateral spine. These defects may be surgically created or the result of traumatic injury to the bone. OsteoFlo HydroFiber is indicated to be packed gently into bony voids or gaps of the pelvis, posterolateral spine, or intervertebral disc space, and may be used either standalone or in combination with autograft as a bone graft extender. The device is resorbed with host bone during the healing process. When used in intervertebral body fusion procedures. OsteoFlo HydroFiber must be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler.

OsteoFlo HydroFiber is a resorbable bone void filler comprised of calcium phosphate, bioglass, in a synthetic polymer binder. The OsteoFlo HydroFiber is intended to be easily packed into osseous defects. The single-use device is supplied sterile and dry. The device requires mixing with aqueous solution (autograft, saline, or bone marrow aspirate) prior to use. OsteoFlo HydroFiber may be used as standalone, equivalent to autograft, or in conjunction with autograft.

The provided text is a 510(k) summary for the OsteoFlo HydroFiber device. It outlines the device's indications, description, and comparison to predicate devices, focusing on demonstrating substantial equivalence based on non-clinical performance testing.

However, the document does not contain any information regarding clinical studies or the performance of an AI/software device. Therefore, I cannot provide details on acceptance criteria, expert adjudication, MRMC studies, standalone performance, or ground truth establishment as requested.

The document primarily focuses on non-clinical performance testing for a bone void filler, which includes:

• Biocompatibility per ISO 10993-1:2018
• Sterilization validation per ISO 11137-1:2006 and ISO 11137-2:2013
• Packaging validation per ISO 11607-1:2009 and ISO 11607-2:2006
• Shelf-life testing per ASTM 1980-16
• Material characterization (x-ray diffraction, particle size, particle porosity and surface area)
• In vivo evaluation in a Lapine Posterolateral Fusion Model

Without information regarding an AI/software component or human reader studies, I cannot fill out the requested table or answer the specific questions related to AI device performance.

Ask a specific question about this device